Chromadex Corporation
CDXC US1710774076
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services. The majority of the revenue is earned from the Consumer Products segment.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -21% | -57% | -15% | 271% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Lopez Carlos Luis SR VP |
7.86 USD |
273 Bought |
2,146 USD |
07/03/2025 | 07/03/2025 |
| Jaksch Frank L Jr |
6.19 USD |
37,161 Sold |
229,956 USD |
13/12/2024 | 13/12/2024 |
| Pamir Ozan CFO |
7.36 USD |
2,907 Bought |
21,397 USD |
22/11/2024 | 22/11/2024 |
| Patrick Kristin |
3.57 USD |
23,000 Sold |
82,110 USD |
23/08/2024 | 23/08/2024 |
| Gerber Brianna CFO |
1.41 USD |
5,000 Bought |
7,050 USD |
01/12/2023 | 01/12/2023 |